MX2017011433A - Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). - Google Patents
Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).Info
- Publication number
- MX2017011433A MX2017011433A MX2017011433A MX2017011433A MX2017011433A MX 2017011433 A MX2017011433 A MX 2017011433A MX 2017011433 A MX2017011433 A MX 2017011433A MX 2017011433 A MX2017011433 A MX 2017011433A MX 2017011433 A MX2017011433 A MX 2017011433A
- Authority
- MX
- Mexico
- Prior art keywords
- cr3r3
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134779P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022738 WO2016149437A1 (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011433A true MX2017011433A (es) | 2017-11-10 |
Family
ID=55640933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011433A MX2017011433A (es) | 2015-03-18 | 2016-03-17 | Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10308652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3271361B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6793658B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102630010B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107635992B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016233289A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017019731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2982446A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA032314B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2797685T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL254520A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017011433A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201707471RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016149437A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102696304B1 (ko) | 2015-03-18 | 2024-08-16 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf의 억제제로서 유용한 헤테로시클릭 화합물 |
| CA2980159A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CA2994703A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JP7121033B2 (ja) | 2017-03-15 | 2022-08-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| DE69814049T2 (de) | 1997-02-25 | 2004-02-19 | The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| ES2254238T3 (es) * | 1999-10-27 | 2006-06-16 | Novartis Ag | Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico. |
| WO2003064422A1 (en) | 2002-01-31 | 2003-08-07 | Daiichi Pharmaceutical Co., Ltd. | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE |
| WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| ES2675583T3 (es) | 2012-06-11 | 2018-07-11 | Ucb Biopharma Sprl | Bencimidazoles moduladores de TNF-alfa |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| CA2888324A1 (en) * | 2012-11-07 | 2014-05-15 | Alexander Flohr | Triazolo compounds |
| ES2529865B8 (es) * | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2015086523A1 (en) | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2809535T3 (es) | 2013-12-09 | 2021-03-04 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores de la actividad de TNF |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2980464T3 (es) | 2014-10-06 | 2024-10-01 | Signal Pharm Llc | Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos |
| CA2980159A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| KR102696304B1 (ko) | 2015-03-18 | 2024-08-16 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf의 억제제로서 유용한 헤테로시클릭 화합물 |
| WO2016168641A1 (en) * | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| MA42034A (fr) * | 2015-05-04 | 2018-03-14 | Actelion Pharmaceuticals Ltd | Composés pipéridiniques tricycliques |
-
2016
- 2016-03-17 KR KR1020177029450A patent/KR102630010B1/ko active Active
- 2016-03-17 CA CA2982446A patent/CA2982446A1/en not_active Abandoned
- 2016-03-17 JP JP2017549093A patent/JP6793658B2/ja active Active
- 2016-03-17 WO PCT/US2016/022738 patent/WO2016149437A1/en not_active Ceased
- 2016-03-17 EA EA201792025A patent/EA032314B1/ru not_active IP Right Cessation
- 2016-03-17 US US15/558,708 patent/US10308652B2/en active Active
- 2016-03-17 ES ES16712646T patent/ES2797685T3/es active Active
- 2016-03-17 EP EP16712646.5A patent/EP3271361B1/en active Active
- 2016-03-17 CN CN201680025154.3A patent/CN107635992B/zh active Active
- 2016-03-17 MX MX2017011433A patent/MX2017011433A/es unknown
- 2016-03-17 SG SG11201707471RA patent/SG11201707471RA/en unknown
- 2016-03-17 AU AU2016233289A patent/AU2016233289A1/en not_active Abandoned
- 2016-03-17 BR BR112017019731-6A patent/BR112017019731A2/pt not_active Application Discontinuation
-
2017
- 2017-09-15 IL IL254520A patent/IL254520A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018508554A (ja) | 2018-03-29 |
| JP6793658B2 (ja) | 2020-12-02 |
| SG11201707471RA (en) | 2017-10-30 |
| US10308652B2 (en) | 2019-06-04 |
| EP3271361A1 (en) | 2018-01-24 |
| BR112017019731A2 (pt) | 2018-05-22 |
| KR20170129811A (ko) | 2017-11-27 |
| CN107635992B (zh) | 2020-05-22 |
| CA2982446A1 (en) | 2016-09-22 |
| ES2797685T3 (es) | 2020-12-03 |
| EP3271361B1 (en) | 2020-04-22 |
| EA201792025A1 (ru) | 2018-01-31 |
| CN107635992A (zh) | 2018-01-26 |
| KR102630010B1 (ko) | 2024-01-25 |
| WO2016149437A1 (en) | 2016-09-22 |
| AU2016233289A1 (en) | 2017-11-09 |
| IL254520A0 (en) | 2017-11-30 |
| US20180111937A1 (en) | 2018-04-26 |
| EA032314B1 (ru) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011433A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). | |
| HK1252623A1 (zh) | 可用作TNFα调节剂的杂环化合物 | |
| MY196474A (en) | [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| MX2017011434A (es) | Compuestos heterociclicos triciclicos sustituidos. | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| EA202091483A1 (ru) | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr | |
| EA201990169A1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| MX2017011577A (es) | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| MX2020006168A (es) | Compuestos de 4-azaindol. | |
| PH12017502050A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| MX2018001173A (es) | Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. | |
| EA202091530A1 (ru) | Диазаиндольные соединения | |
| MD4779B1 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| EA201990657A1 (ru) | Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| UA119458C2 (uk) | Сполуки піридину пладієноліду та способи застосування | |
| MX377329B (es) | Moduladores de ror gamma (ror?). | |
| PH12017500095A1 (en) | Imidazopyridazine compounds |